Stem Cells for Diabetes: Can They Restore Insulin Production?

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Doctor Bangkok. Last reviewed: September 2026

Most patients I see who ask about stem cells for diabetes have done their reading. They are managing the condition day to day, often without the specialist follow-up they had back home, and they want to know if there is something more. The questions are almost always the same: is this real, is it safe, and does it actually work?

The honest answer is yes, it is real. The evidence is growing. For the right patient, it can make a meaningful difference. But it is not a simple fix, and it is not the same treatment for Type 1 as it is for Type 2. Here is a clear picture of where things actually stand.

Type 1 vs Type 2 Diabetes: Why the Stem Cell Approach Differs

This distinction matters more than most clinic pages let on. In Type 1 diabetes, your immune system has attacked and destroyed the beta cells in your pancreas. Those are the cells that make insulin. Stem cell therapy in Type 1 has two goals: calm the immune system so it stops destroying beta cells, and try to restore the ones already lost.

In Type 2, your pancreas still produces insulin, but your body has stopped responding to it well. Beta cells may also be worn down from years of overwork. Here, the goal is reducing insulin resistance and restoring better beta cell function.

The cell types used, the treatment approach, and the expected outcomes all differ between the two conditions. Bundling them together leads to patients going in with the wrong expectations.

Types of Stem Cells Used in Diabetes Treatment

The most studied option is mesenchymal stem cells, or MSCs. These come from several sources. Umbilical cord-derived MSCs, sometimes called Wharton’s jelly MSCs, are widely used because they are readily available and well tolerated. Bone marrow-derived stem cells have been studied mainly in Type 1 diabetes for their immune-modulating effects.

Induced pluripotent stem cells, or iPSCs, are a newer category. These are adult cells guided toward becoming insulin-producing cells. In 2024, the first published case of iPSC-derived islet transplantation reported insulin independence at 75 days. That is a genuinely significant result. It is also one case, and the research is still early.

GMP-certified cell sourcing, meaning cells processed to pharmaceutical-grade standards, is a baseline requirement for any provider you consider.

What Clinical Trials Actually Show About Stem Cells for Diabetes

The gap between clinic marketing and trial data is wide. Pay close attention here.

The most discussed recent result comes from a Phase 1/2 trial of zimislecel, previously called VX-880, published in the New England Journal of Medicine. A significant proportion of Type 1 patients achieved insulin independence at one year. That is a landmark result. These patients did require ongoing immunosuppression medication to prevent rejection, which is not suitable for everyone and carries its own risks.

In Type 2 diabetes, published meta-analyses show MSC therapy can reduce HbA1c, your average blood sugar over roughly three months, and improve C-peptide levels, which reflect how much insulin your pancreas is still producing. The reductions are clinically meaningful but variable. Patients with earlier-stage disease tend to respond better.

This evidence base is real. It is also still maturing. Honest clinicians will tell you both things at once.

Beyond Insulin: Can Stem Cells Help Diabetic Complications?

For many expats managing diabetes in Bangkok, the bigger day-to-day problem is not insulin alone. It is what years of uncontrolled or under-managed diabetes have already done to other parts of the body.

Diabetic neuropathy, the nerve damage that causes numbness, pain, or weakness usually in the feet and legs, is an active area of MSC research. Early-phase trials show some promising signals around nerve repair and inflammation reduction. Diabetic kidney damage and diabetic foot ulcers are also being studied as targets for MSC-based therapy.

The evidence here is less mature than for insulin production outcomes. But for patients already managing long-term complications, it is a meaningful question worth raising in a proper consultation.

What to Realistically Expect From Stem Cell Therapy

I will be direct about this. Stem cell therapy for diabetes is not a guaranteed cure. For most patients, the realistic goal is reduced insulin requirements, more stable blood sugar, and better quality of life. Full insulin independence is a possible outcome for some, not a standard promise.

Patients with early-stage Type 1 diabetes who still have some remaining beta cell function, shown by detectable C-peptide levels, tend to see the best results. Long-standing Type 1 with near-total beta cell loss is a harder target. In Type 2, patients who still have meaningful beta cell reserve and have not been on insulin for many years tend to respond better.

Anyone offering guaranteed results before reviewing your full history is not someone you should trust with this decision.

Choosing a Stem Cell Provider for Diabetes in Bangkok

Bangkok has a wide range of stem cell providers. Some are excellent. Some are not. The risk of going to an unregulated facility is real and documented: infection, poor cell quality, and in rare cases more serious complications.

Before committing to anything, check that the clinic holds Thai FDA licensing for cell-based therapies. The cells should come from a GMP-certified source. You should receive a full clinical assessment before any protocol or price is discussed. If a clinic quotes you a package before reviewing your medical history, that is a serious warning sign.

You also want to know exactly what cell type you are receiving, what dose, and what the follow-up plan looks like. Responsible providers build monitoring into the process, because outcomes need to be tracked and the approach may need to be adjusted.

Getting Started With Stem Cell Therapy for Diabetes in Bangkok

Most patients I see at Doctor Bangkok come in having done a lot of reading but without a clear sense of whether they are actually a candidate. That is exactly where to start. Reading is not the same as being assessed.

A first consultation covers your diabetes type and duration, your current insulin regimen if applicable, your most recent HbA1c and C-peptide results, and any complications you are already managing. That last part, an honest conversation about what stem cell therapy can and cannot offer you, is the most important part of the visit.

If you are an expat managing diabetes in Bangkok without consistent specialist care, that assessment alone is a useful reset, regardless of whether stem cell therapy ends up being right for you. You can review your options on our stem cell therapy page or book directly for a face-to-face assessment. Patients travelling from outside Thailand should also check whether post-treatment monitoring can continue with a physician after they return home.

DR Ponlawat

Dr. Ponlawat Pitsuwan is a physician at Doctor Bangkok, a private clinic in central Bangkok. He sees expats, residents, and medical tourists for general medicine, wellness consultations, and IV therapy. His focus is straightforward, evidence-based care delivered in plain language.